Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALT NASDAQ:CDTX NASDAQ:HROW NASDAQ:WVE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALTAltimmune$3.61-2.2%$5.14$2.90▼$11.16$292.80M-0.013.61 million shs1.80 million shsCDTXCidara Therapeutics$62.90-0.6%$41.88$10.14▼$66.94$1.27B1.18646,574 shs302,038 shsHROWHarrow$31.23-1.7%$31.76$20.85▼$59.23$1.15B0.41442,110 shs530,570 shsWVEWAVE Life Sciences$8.63+6.5%$7.22$5.04▼$16.74$1.37B-0.951.67 million shs1.84 million shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALTAltimmune-2.17%-11.52%-26.33%-37.44%-43.24%CDTXCidara Therapeutics-0.65%+1.70%+31.40%+190.00%+383.85%HROWHarrow-1.67%-13.71%+2.16%+20.91%+21.14%WVEWAVE Life Sciences+6.54%+2.74%+27.85%+6.54%+30.56%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALTAltimmune2.2333 of 5 stars3.43.00.00.01.31.70.6CDTXCidara Therapeutics2.8836 of 5 stars2.62.00.04.60.61.70.0HROWHarrow2.5074 of 5 stars3.51.00.00.03.02.50.6WVEWAVE Life Sciences4.6935 of 5 stars4.52.00.04.82.24.20.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALTAltimmune 2.75Moderate Buy$18.20404.16% UpsideCDTXCidara Therapeutics 3.11Buy$57.29-8.93% DownsideHROWHarrow 3.00Buy$63.83104.40% UpsideWVEWAVE Life Sciences 2.93Moderate Buy$20.36135.89% UpsideCurrent Analyst Ratings BreakdownLatest ALT, HROW, WVE, and CDTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/31/2025WVEWAVE Life SciencesWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$24.00 ➝ $21.007/28/2025WVEWAVE Life SciencesOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$24.007/16/2025WVEWAVE Life SciencesCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$16.007/11/2025HROWHarrowCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$76.007/10/2025ALTAltimmuneThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong Sell7/10/2025ALTAltimmuneJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$25.00 ➝ $15.007/9/2025CDTXCidara TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$69.006/30/2025CDTXCidara TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$59.006/27/2025ALTAltimmuneWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform ➝ Market Perform6/27/2025ALTAltimmuneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.006/24/2025CDTXCidara TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALTAltimmune$20K14,640.36N/AN/A$1.74 per share2.07CDTXCidara Therapeutics$1.27M998.48N/AN/A$14.92 per share4.22HROWHarrow$199.61M5.74$0.13 per share232.26$1.95 per share16.02WVEWAVE Life Sciences$108.30M12.68N/AN/A$0.88 per share9.81Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALTAltimmune-$95.06M-$1.26N/AN/AN/A-451,200.00%-65.44%-58.43%8/6/2025 (Estimated)CDTXCidara Therapeutics-$169.83M-$29.47N/AN/AN/AN/A-73.04%-54.28%8/7/2025 (Estimated)HROWHarrow-$17.48M-$0.56N/A78.08N/A-10.19%-25.01%-4.27%8/11/2025 (Estimated)WVEWAVE Life Sciences-$97.01M-$0.84N/AN/AN/AN/A-78.45%-41.51%N/ALatest ALT, HROW, WVE, and CDTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025ALTAltimmune-$0.3006N/AN/AN/A$0.00 millionN/A8/11/2025Q2 2025HROWHarrow$0.01N/AN/AN/A$64.23 millionN/A8/7/2025Q2 2025CDTXCidara Therapeutics-$1.87N/AN/AN/AN/AN/A7/30/2025Q2 2025WVEWAVE Life Sciences-$0.29-$0.31-$0.02-$0.31$11.52 million$8.70 million5/13/2025Q1 2025ALTAltimmune-$0.35-$0.26+$0.09-$0.26$0.00 million$0.01 million5/8/2025Q1 2025CDTXCidara Therapeutics-$5.45-$1.66+$3.79-$1.66N/AN/A5/8/2025Q1 2025HROWHarrow$0.02-$0.38-$0.40-$0.50$57.00 million$47.83 million5/8/2025Q1 2025WVEWAVE Life Sciences-$0.27-$0.29-$0.02-$0.29$11.65 million$9.18 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALTAltimmuneN/AN/AN/AN/AN/ACDTXCidara TherapeuticsN/AN/AN/AN/AN/AHROWHarrowN/AN/AN/AN/AN/AWVEWAVE Life SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALTAltimmuneN/A15.8515.85CDTXCidara TherapeuticsN/A3.873.87HROWHarrow2.010.910.85WVEWAVE Life SciencesN/A2.562.95Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALTAltimmune78.05%CDTXCidara Therapeutics35.82%HROWHarrow72.76%WVEWAVE Life Sciences89.73%Insider OwnershipCompanyInsider OwnershipALTAltimmune4.10%CDTXCidara Therapeutics3.89%HROWHarrow15.16%WVEWAVE Life Sciences23.98%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALTAltimmune5081.11 million77.78 millionOptionableCDTXCidara Therapeutics9020.16 million19.38 millionNo DataHROWHarrow18036.69 million31.12 millionOptionableWVEWAVE Life Sciences240159.14 million118.26 millionOptionableALT, HROW, WVE, and CDTX HeadlinesRecent News About These CompaniesWAVE Life Sciences (NASDAQ:WVE) Trading 6.3% Higher - Here's Why5 hours ago | marketbeat.comWAVE Life Sciences (NASDAQ:WVE) Posts Quarterly Earnings Results, Misses Expectations By $0.02 EPSAugust 2 at 12:39 PM | marketbeat.comNeed To Know: The Consensus Just Cut Its Wave Life Sciences Ltd. (NASDAQ:WVE) Estimates For 2025August 2 at 10:58 AM | finance.yahoo.comWells Fargo & Company Cuts WAVE Life Sciences (NASDAQ:WVE) Price Target to $21.00August 2 at 2:07 AM | americanbankingnews.comWAVE Life Sciences (NASDAQ:WVE) Price Target Lowered to $21.00 at Wells Fargo & CompanyAugust 1 at 1:05 PM | marketbeat.comWAVE Life Sciences Ltd (WVE) Q2 2025 Earnings Call Highlights: Progress in RNA Editing Amid ...July 31 at 6:15 AM | finance.yahoo.comWave (WVE) Q2 Revenue Drops 56%July 31 at 3:10 AM | fool.comWAVE Life Sciences Ltd. (NASDAQ:WVE) Receives Consensus Rating of "Moderate Buy" from AnalystsJuly 31 at 2:44 AM | marketbeat.comWave Life Sciences signals key Q3 and Q4 data catalysts as INHBE and AATD programs advanceJuly 31 at 2:14 AM | msn.comWave Life Sciences Ltd. (WVE) Q2 2025 Earnings Call TranscriptJuly 30 at 10:05 PM | seekingalpha.comWAVE Life Sciences Ltd (WVE) Q2 2025 Earnings Report Preview: What To ExpectJuly 30 at 3:11 PM | finance.yahoo.comWaveLife Flat on Q2 ResultsJuly 30 at 10:11 AM | baystreet.caWave Life Sciences (WVE) Reports Q2 Loss, Misses Revenue EstimatesJuly 30 at 10:01 AM | zacks.comWave Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business UpdateJuly 30 at 7:30 AM | globenewswire.comWave Life Sciences Q2 2025 Earnings PreviewJuly 29, 2025 | msn.comOppenheimer Initiates Coverage of Wave Life Sciences (WVE) with Outperform RecommendationJuly 29, 2025 | msn.comWAVE Life Sciences (NASDAQ:WVE) Shares Gap Up - Time to Buy?July 28, 2025 | marketbeat.comWAVE Life Sciences (WVE) to Release Quarterly Earnings on WednesdayJuly 25, 2025 | marketbeat.comNew York State Common Retirement Fund Acquires 41,429 Shares of WAVE Life Sciences Ltd. (NASDAQ:WVE)July 25, 2025 | marketbeat.comWave Life Sciences Second Quarter 2025 Financial Results Scheduled for July 30, 2025July 23, 2025 | globenewswire.comHussman Strategic Advisors Inc. Has $848,000 Stake in WAVE Life Sciences Ltd. (NASDAQ:WVE)July 19, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesRocket Lab: A Parabolic Run Meets a Healthy PullbackBy Ryan Hasson | July 23, 2025View Rocket Lab: A Parabolic Run Meets a Healthy PullbackForget the Weak Dollar—These 3 Travel Stocks Are Still Taking OffBy Chris Markoch | July 6, 2025View Forget the Weak Dollar—These 3 Travel Stocks Are Still Taking OffDo They Know Something? Insiders & Congress Buy UnitedHealthBy Brian O'Connell | July 9, 2025View Do They Know Something? Insiders & Congress Buy UnitedHealthInsiders Spent Millions on These 3 Stocks Over the Past 2 MonthsBy Leo Miller | July 17, 2025View Insiders Spent Millions on These 3 Stocks Over the Past 2 MonthsHealthcare Stocks Hit Valuation Bottom, 3 Names to ReboundBy Gabriel Osorio-Mazilli | July 23, 2025View Healthcare Stocks Hit Valuation Bottom, 3 Names to ReboundALT, HROW, WVE, and CDTX Company DescriptionsAltimmune NASDAQ:ALT$3.61 -0.08 (-2.17%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$3.64 +0.04 (+0.97%) As of 08/1/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.Cidara Therapeutics NASDAQ:CDTX$62.90 -0.41 (-0.65%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$60.00 -2.90 (-4.61%) As of 08/1/2025 06:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.Harrow NASDAQ:HROW$31.23 -0.53 (-1.67%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$31.85 +0.62 (+1.99%) As of 08/1/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.WAVE Life Sciences NASDAQ:WVE$8.63 +0.53 (+6.54%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$8.39 -0.24 (-2.79%) As of 08/1/2025 07:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale Is PG&E an AI Power Play? Why Options Traders Are Betting Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
